NeuroSense Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ciprofloxacin/celecoxib (PrimeC) / NeuroSense Therap
2022-002185-32: ALS clinical trial, Randomized, double-blind, placebo-controlled Study with an Open label extension in subjects with ALS Studio clinico randomizzato, in doppio cieco, controllato con placebo sulla SLA con estensione in aperto nei soggetti affetti da SLA

Not yet recruiting
2
69
Europe
PrimeC, [N/A], Tablet
NeuroSense Therapeutics Ltd, NeuroSense Therapeutics Ltd.
Amyotrophic lateral sclerosis (ALS) Sclerosi Laterale Amiotrofica (SLA), ALS is a disease of the nerve cells in the brain and spinal cord that control voluntary muscle movement La SLA è una malattia delle cellule nervose del cervello e del midollo spinale che controlla il movimento muscolare volontario, Diseases [C] - Nervous System Diseases [C10]
 
 
PARADIGM, NCT05357950 / 2022-002185-32: A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS

Active, not recruiting
2
69
Europe, Canada, RoW
PrimeC, Placebo
NeuroSense Therapeutics Ltd., NeuroSense Therapeutics Ltd.
Amyotrophic Lateral Sclerosis, ALS
11/23
11/24
RoAD, NCT06185543: A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.

Recruiting
2
20
RoW
PrimeC, Placebo
NeuroSense Therapeutics Ltd.
Alzheimer Disease
11/25
11/25
NCT05436678: A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject

Completed
1
19
US
PrimeC 748 mg, Ciprofloxacin 750 MG, Celecoxib 200mg
NeuroSense Therapeutics Ltd.
Pharmacokinetics
08/22
10/22
ChiCTR2500095560: The therapeutic effect of the combination of ciprofloxacin and celecoxib of amyotrophic lateral sclerosis

Not yet recruiting
N/A
60
 
None; None
Southern Medical University Southern Hospital; Southern Medical University Southern Hospital, Self-funded
Patients diagnosed with ALS according to the revised EI Escorial diagnostic criteria of the World Federation of Neurology (WFN) in 1994 (revised in 1998). To diagnose ALS, you need to: 1. Clinical, electrophysiological or neuropathological examination with signs of LMN (lower motor neuron) degeneration; 2. Clinical examination shows signs of UMN (upper motor neuron) degeneration; 3. Progressive de
 
 
ciprofloxacin/celecoxib (CogniC) / NeuroSense Therap
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ciprofloxacin/celecoxib (PrimeC) / NeuroSense Therap
2022-002185-32: ALS clinical trial, Randomized, double-blind, placebo-controlled Study with an Open label extension in subjects with ALS Studio clinico randomizzato, in doppio cieco, controllato con placebo sulla SLA con estensione in aperto nei soggetti affetti da SLA

Not yet recruiting
2
69
Europe
PrimeC, [N/A], Tablet
NeuroSense Therapeutics Ltd, NeuroSense Therapeutics Ltd.
Amyotrophic lateral sclerosis (ALS) Sclerosi Laterale Amiotrofica (SLA), ALS is a disease of the nerve cells in the brain and spinal cord that control voluntary muscle movement La SLA è una malattia delle cellule nervose del cervello e del midollo spinale che controlla il movimento muscolare volontario, Diseases [C] - Nervous System Diseases [C10]
 
 
PARADIGM, NCT05357950 / 2022-002185-32: A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS

Active, not recruiting
2
69
Europe, Canada, RoW
PrimeC, Placebo
NeuroSense Therapeutics Ltd., NeuroSense Therapeutics Ltd.
Amyotrophic Lateral Sclerosis, ALS
11/23
11/24
RoAD, NCT06185543: A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.

Recruiting
2
20
RoW
PrimeC, Placebo
NeuroSense Therapeutics Ltd.
Alzheimer Disease
11/25
11/25
NCT05436678: A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject

Completed
1
19
US
PrimeC 748 mg, Ciprofloxacin 750 MG, Celecoxib 200mg
NeuroSense Therapeutics Ltd.
Pharmacokinetics
08/22
10/22
ChiCTR2500095560: The therapeutic effect of the combination of ciprofloxacin and celecoxib of amyotrophic lateral sclerosis

Not yet recruiting
N/A
60
 
None; None
Southern Medical University Southern Hospital; Southern Medical University Southern Hospital, Self-funded
Patients diagnosed with ALS according to the revised EI Escorial diagnostic criteria of the World Federation of Neurology (WFN) in 1994 (revised in 1998). To diagnose ALS, you need to: 1. Clinical, electrophysiological or neuropathological examination with signs of LMN (lower motor neuron) degeneration; 2. Clinical examination shows signs of UMN (upper motor neuron) degeneration; 3. Progressive de
 
 
ciprofloxacin/celecoxib (CogniC) / NeuroSense Therap
No trials found

Download Options